Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Pretomanid for tuberculosis: a systematic review
Tinne Gils et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Human ancient DNA analyses reveal the high burden of tuberculosis in Europeans over the last 2,000 years
Gaspard Kerner et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2021)
A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response
Yang Luo et al.
NATURE GENETICS (2021)
First description of the katG gene deletion in a Mycobacterium tuberculosis clinical isolate and its impact on the mycobacterial fitness
Flavio De Maio et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2021)
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial
Robert S. Wallis et al.
LANCET RESPIRATORY MEDICINE (2021)
Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis
Ming-Gui Wang et al.
BMC INFECTIOUS DISEASES (2021)
Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis
Ivana Palucci et al.
FRONTIERS IN IMMUNOLOGY (2020)
Antimycobacterial Effects of Everolimus in a Human Granuloma Model
David Ashley et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
Justyna Kikut et al.
NUTRIENTS (2020)
Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in Mycobacterium tuberculosis Infection
Stephen Cerni et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study
Stefan P. Berger et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles
Basem Battah et al.
MOLECULES (2019)
Cytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit Intracellular Mycobacterium tuberculosis Growth
Shahin Ranjbar et al.
ISCIENCE (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
A genomic perspective on HLA evolution
Diogo Meyer et al.
IMMUNOGENETICS (2018)
Host-directed therapies for bacterial and viral infections
Stefan H. E. Kaufmann et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1β-induced autophagy
Alessandra Romagnoli et al.
CELL DEATH & DISEASE (2018)
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies
Narges Alipanah et al.
PLOS MEDICINE (2018)
Harnessing the mTOR Pathway for Tuberculosis Treatment
Pooja Singh et al.
FRONTIERS IN MICROBIOLOGY (2018)
Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship
Marine Deppenweiler et al.
PHARMACOLOGICAL RESEARCH (2017)
Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma
So-Yeon Jeon et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2017)
Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary Specimens
Michela Sali et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2016)
Human ULK1 Variation and Susceptibility to Mycobacterium tuberculosis Infection
David J. Horne et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages
David Stucki et al.
NATURE GENETICS (2016)
Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use
E. Guirao-Arrabal et al.
TRANSPLANT INFECTIOUS DISEASE (2016)
Incidence and Risk Factors for Tuberculosis After Liver Transplantation in an Endemic Area: A Nationwide Population-Based Matched Cohort Study
C. -Y. Chen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Quantitative analysis of autophagic flux by confocal pH-imaging of autophagic intermediates
Giuseppe Maulucci et al.
AUTOPHAGY (2015)
PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data
Silke Feuerriegel et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2015)
Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient
Jolanta Barbara Fijałkowska-Morawska et al.
Annals of Transplantation (2015)
Reactivation Versus Clearance of Mycobacterium tuberculosis Using Mammalian Target of Rapamycin Inhibitors in Patients With Cancer Can Be Context Dependent
Salvador Vale
JOURNAL OF CLINICAL ONCOLOGY (2013)
The role of therapeutic monitoring of everolimus in solid organ transplantation
Vincent H. Mabasa et al.
THERAPEUTIC DRUG MONITORING (2005)
Clinical pharmacokinetics of sirolimus
K Mahalati et al.
CLINICAL PHARMACOKINETICS (2001)
Share Paper
